OpGen

OpGen P/B

The P/B (Price-to-Book Ratio) of OpGen (OPGN) as of Oct 22, 2026 is 11.46. In the previous year, P/B (Price-to-Book Ratio) was 49.48 — a change of -76.83% (lower).

P/B

11.46

YoY

-76.83%

Last updated:

P/B (Price-to-Book Ratio) of OpGen is 2025 11.46 . P/B (Price-to-Book Ratio) of OpGen was 2024 49.48 . It decreases by -76.83% lower compared to the previous year.

The OpGen P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
110.38 USD
Jan 1, 2019
85.07 USD
Jan 1, 2020
17.23 USD
Jan 1, 2021
8.86 USD
Jan 1, 2022
48.21 USD
Jan 1, 2023
-31.59 USD
Jan 1, 2024
49.48 USD
Jan 1, 2025
11.46 USD
The OpGen P/B history
YEARP/BYoY
11.46-76.83%
49.48-256.65%
-31.59-165.53%
48.21+444.05%
8.86-48.59%
17.23-79.74%
85.07-22.93%
110.38-57.66%
260.69+126.09%
115.31+136.50%
48.76-207.67%
-45.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

P/B (Price-to-Book Ratio) of OpGen is 11.46 in 2025.

P/B (Price-to-Book Ratio) of OpGen changed from 49.48 to 11.46, representing a -76.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) OpGen since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s OpGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OpGen

All Key Metrics — OpGen